Remove Compounding Remove FDA Remove Immunization
article thumbnail

STAT+: Pharmalittle: We’re reading about compounders suing the FDA, Biogen turning to telehealth, and more

STAT

… A trade group representing large compounding pharmacies has sued the U.S. Moreover, the trade group maintained the FDA move was “unlawful,” because it failed to follow so-called rule-making procedures and provide proper notice of its plans. Have a grand day, everyone, and do stay in touch. ” A U.S.

article thumbnail

7 health benefits of raspberry leaf tea

The Checkup by Singlecare

Red raspberry leaves are rich in tannins (a chemical compound) and flavonoids (a plant pigment), which both have antioxidant properties, according to research in Antioxidants journal. Antioxidants are often associated with a healthy immune system, but they may also stave off disease by protecting cells from damage caused by free radicals.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Pharmalittle: We’re reading about a soft-tissue cancer drug approval, the Zepbound shortage ending, and more

STAT

… The FDA has approved a cutting-edge treatment for a rare soft tissue cancer, STAT tells us. The therapy equips T cells, an important class of immune cell, to target synovial sarcomas, cancers that can form in muscles and ligaments. CEO David Ricks expects Zepbound to come off the FDA’s shortage list in the coming days.

article thumbnail

Low Dose Naltrexone and Hashimoto’s

The Thyroid Pharmacist

You may be familiar with naltrexone, which is an FDA-approved medication that has been used since the 1980s for opioid withdrawal. However, low doses of this medication (hence, low dose naltrexone or LDN), have been found to modulate the immune system and have shown promise in improving cases of autoimmune disease. Doses of 1.5-4.5

article thumbnail

Injectable drug delivery market to value $1139.4b by 2029

European Pharmaceutical Review

percent compound annual growth rate (CAGR) between 2024 to 2029. Injectable vaccines activate the immune system to help to prevent infectious conditions such as influenza. A new report by MarketsandMarkets has predicted that the injectable drug delivery market will reach an 8.6 The market is anticipated to value $1139.4

article thumbnail

Company profile: NeoImmuneTech

pharmaphorum

Amplifying and reinvigorating persistent T cell immunity has become a much-needed path to enhance anti-tumor efficacy. By enabling strong CD8 T-cell infiltration in cold tumor tissues, NT-I7, a compound developed by NeoImmuneTech, is capable of promoting a microenvironment that contributes to clinical efficacy, when combined with a CPI.

article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

With alpha particles, you must be very careful how the drug is made to ensure that the compound remains stable between manufacturing and use. This has been demonstrated recently with PLUVICTO ® , which was the first US Food and Drug Administration (FDA)-approved targeted radioligand therapy for eligible patients with prostate cancer.